NewAmsterdam Pharma Company N.V. (NewAmsterdam Pharma Company N.V) aksje
NAMS
Stengt$32.11+0.40 (+1.26%)
Laster graf...
NewAmsterdam Pharma Company N.V
Market Cap
$3,753,786,624
Åpning31.69
Høy32.46
Lav31.33
Volum1.03M
P/EN/A
Markedsverdi3.75B
52-ukers høy42.21
52-ukers lav17.63
Gj.sn. volum1.17M
UtbytteN/A
Beta0.03
EPS-1.78
Om NewAmsterdam Pharma Company N.V. (NewAmsterdam Pharma Company N.V) aksje
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Selskapsinformasjon
Børs: NasdaqGM (NGM)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
Gooimeer 2-35
1411 DC Naarden, Netherlands
1411 DC Naarden, Netherlands
Telefon: + 31 35 206 2971
Nettside: https://www.newamsterdampharma.com
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.
Anbefaling:1.36 - Stærk køb
Laveste kursmål
37.59
↑ 17.1%
Gjennomsnittlig kursmål
50.23
↑ 56.4%
Median kursmål
50.45
↑ 57.1%
Høyeste kursmål
59.58
↑ 85.6%